Amylyx Pharmaceuticals Q2 2024 Earnings Report $3.94 -0.34 (-7.94%) (As of 05:44 PM ET) Earnings HistoryForecast Amylyx Pharmaceuticals EPS ResultsActual EPS-$0.73Consensus EPS -$0.38Beat/MissMissed by -$0.35One Year Ago EPS$0.31Amylyx Pharmaceuticals Revenue ResultsActual Revenue($1.02) millionExpected Revenue$18.83 millionBeat/MissMissed by -$19.85 millionYoY Revenue GrowthN/AAmylyx Pharmaceuticals Announcement DetailsQuarterQ2 2024Date8/8/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseAMLX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Uncover the Top Gold Stock of the Bull Market (Ad)Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Click here to see how this opportunity could transform your portfolio. Amylyx Pharmaceuticals Earnings HeadlinesAmylyx announces design of LUCIDITY clinical trialDecember 5, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Keros Therapeutics (KROS), Century Therapeutics (IPSC)December 5, 2024 | markets.businessinsider.comUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?December 18, 2024 | Huge Alerts (Ad)Baird Upgrades Amylyx Pharmaceuticals (AMLX)November 19, 2024 | msn.comTwist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On MondayNovember 18, 2024 | benzinga.comAmylyx upgraded to Outperform from Neutral at BairdNovember 18, 2024 | markets.businessinsider.comSee More Amylyx Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amylyx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amylyx Pharmaceuticals and other key companies, straight to your email. Email Address About Amylyx PharmaceuticalsAmylyx Pharmaceuticals (NASDAQ:AMLX), a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.View Amylyx Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
